-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, China's innovative drug industry has flourished.
Data shows that the number of new drug clinical trials in China has continued to grow since 2016
.
In addition, as of December 2021, the number of new drug projects for the first time has reached 198, and the number of new drugs listed has reached 97 over the whole of 2020
.
According to incomplete statistics, in 2021, at least 17 Chinese new drug R&D companies will usher in their first approved products
.
For example, in 2021, the oral selective nuclear export protein (XPO1) inhibitor Selinexol introduced by Antengene has been approved in South Korea and mainland China successively.
The drug is indicated for multiple myeloma and diffuse large B-cell lymphoma.
.
It is reported that this is the first approved product of Antengene since its establishment
.
In December 2021, Orebatinib Tablets, a class 1 new drug developed by Shunjian Pharma, a wholly-owned subsidiary of Ascentage Pharma, was approved by the NMPA for marketing
.
Orebatinib is an original class 1 new drug of Ascentage Pharma for the treatment of adult patients with chronic myeloid leukemia (CML) with T315I mutation who are resistant to any tyrosine kinase inhibitor (TKI) in the chronic phase or accelerated phase
.
It is understood that Ascentage Pharma is an original innovative drug research and development enterprise in the clinical development stage based in China and facing the world
.
In November 2021, a subcutaneous injection of PD-L1 inhibitor envolimab jointly developed by the two companies, Sidi Pharmaceuticals and Corning Jereh, was approved by the NMPA for marketing
.
The drug is indicated for the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors, including selected patients with advanced colorectal cancer and other advanced solid tumors tumor patients
.
In September 2021, WuXi Junuo's self-developed Ruiqiorenza injection was approved by the NMPA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after second-line or above systemic therapy.
The first approved product of WuXi Junuo
.
In August, the Sepalizumab injection declared by Yuheng Bio was approved by NMPA for the treatment of second-line or above relapsed or refractory classical Hodgkin lymphoma, becoming the first product approved by Yuheng Bio.
.
In addition, pharmaceutical companies such as Kangfang Bio, Shenzhou Cell, Real Bio, Fosun Kite, Zejing Pharmaceutical, Mengke Pharmaceutical, Huahao Zhongtian, Rongchang Bio, CStone Pharmaceuticals, Alys Pharmaceuticals, and Tengsheng Biopharmaceuticals also The first new drug will be approved in 2021
.
In recent years, driven by national policies, China's innovative drugs have ushered in a golden development cycle.
According to the industry, ADCs, dual antibodies, and CAR-T cells are three important directions for new drug research and development, especially for tumor treatment.
These three directions are very likely to produce drugs with breakthrough effects, and domestic and foreign R&D forces have also been invested in these three fields
.
Looking forward to 2022, China's innovative drugs will usher in a better development situation
.
According to the industry, according to the number of declared projects, it is expected that the number of new drugs on the market in 2022 will usher in a greater increase, and the launch of new drugs in China may achieve a blowout
.
Data shows that the number of new drug clinical trials in China has continued to grow since 2016
.
In addition, as of December 2021, the number of new drug projects for the first time has reached 198, and the number of new drugs listed has reached 97 over the whole of 2020
.
According to incomplete statistics, in 2021, at least 17 Chinese new drug R&D companies will usher in their first approved products
.
For example, in 2021, the oral selective nuclear export protein (XPO1) inhibitor Selinexol introduced by Antengene has been approved in South Korea and mainland China successively.
The drug is indicated for multiple myeloma and diffuse large B-cell lymphoma.
.
It is reported that this is the first approved product of Antengene since its establishment
.
In December 2021, Orebatinib Tablets, a class 1 new drug developed by Shunjian Pharma, a wholly-owned subsidiary of Ascentage Pharma, was approved by the NMPA for marketing
.
Orebatinib is an original class 1 new drug of Ascentage Pharma for the treatment of adult patients with chronic myeloid leukemia (CML) with T315I mutation who are resistant to any tyrosine kinase inhibitor (TKI) in the chronic phase or accelerated phase
.
It is understood that Ascentage Pharma is an original innovative drug research and development enterprise in the clinical development stage based in China and facing the world
.
In November 2021, a subcutaneous injection of PD-L1 inhibitor envolimab jointly developed by the two companies, Sidi Pharmaceuticals and Corning Jereh, was approved by the NMPA for marketing
.
The drug is indicated for the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors, including selected patients with advanced colorectal cancer and other advanced solid tumors tumor patients
.
In September 2021, WuXi Junuo's self-developed Ruiqiorenza injection was approved by the NMPA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after second-line or above systemic therapy.
The first approved product of WuXi Junuo
.
In August, the Sepalizumab injection declared by Yuheng Bio was approved by NMPA for the treatment of second-line or above relapsed or refractory classical Hodgkin lymphoma, becoming the first product approved by Yuheng Bio.
.
In addition, pharmaceutical companies such as Kangfang Bio, Shenzhou Cell, Real Bio, Fosun Kite, Zejing Pharmaceutical, Mengke Pharmaceutical, Huahao Zhongtian, Rongchang Bio, CStone Pharmaceuticals, Alys Pharmaceuticals, and Tengsheng Biopharmaceuticals also The first new drug will be approved in 2021
.
In recent years, driven by national policies, China's innovative drugs have ushered in a golden development cycle.
According to the industry, ADCs, dual antibodies, and CAR-T cells are three important directions for new drug research and development, especially for tumor treatment.
These three directions are very likely to produce drugs with breakthrough effects, and domestic and foreign R&D forces have also been invested in these three fields
.
Looking forward to 2022, China's innovative drugs will usher in a better development situation
.
According to the industry, according to the number of declared projects, it is expected that the number of new drugs on the market in 2022 will usher in a greater increase, and the launch of new drugs in China may achieve a blowout
.
